On Nov 14, major Wall Street analysts update their ratings for $Progyny (PGNY.US)$, with price targets ranging from $17 to $22.
BofA Securities analyst Allen Lutz maintains with a buy rating, and maintains the target price at $21.
Barclays analyst Stephanie Davis maintains with a buy rating, and adjusts the target price from $30 to $17.
Jefferies analyst Glen Santangelo maintains with a buy rating, and adjusts the target price from $24 to $19.
Cantor Fitzgerald analyst Sarah James maintains with a buy rating, and adjusts the target price from $25 to $22.
Furthermore, according to the comprehensive report, the opinions of $Progyny (PGNY.US)$'s main analysts recently are as follows:
Progyny's stock experienced an 11% decline following the earnings announcement. This was a result of better-than-anticipated selling season outcomes being eclipsed by repeated reductions concerning atypical usage, which has raised concerns regarding forecasting models. While there is an anticipation for evidence of accurate forecasting, there is also an acknowledgment of the need for a more cautious outlook on the company's guidance.
Q3 results indicate continuing pressure due to an unfavorable utilization mix, and there's limited visibility on when these conditions might shift. Despite the uncertainty caused by utilization trends, there remains a positive outlook on the fertility end-market and Progyny's dominant market position.
The firm is revising its projections to account for the outcomes of the selling season. This includes the addition of 1.1 million members, which is somewhat offset by approximately 700,000 due to a previously disclosed client departure. Additionally, the firm is adopting a more cautious stance on the expected utilization and composition for Q4 and the full year of FY25.
Here are the latest investment ratings and price targets for $Progyny (PGNY.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
